Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Novo Nordisk A/S
Richard Pratley; Aslam Amod; Søren Tetens Hoff; Takashi Kadowaki; Ildiko Lingvay; Michael Nauck; Karen Boje Pedersen; Trine Saugstrup; Juris J Meier